文献速递肝病

使用MRI-PDFF和瞬时弹性成像筛查有NAFLD风险的HIV患者:一项欧洲多中心前瞻性研究

Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-04-15

本研究为欧洲多中心前瞻性研究,纳入442例有NAFLD风险的HIV单一感染患者,分析402例。结果显示64%存在脂肪变(MRI-PDFF≥5%),其中11.3%有提示晚期纤维化的肝硬度≥9.6 kPa。CAP诊断中重度脂肪变的曲线下面积为0.86。

要点

  • HIV单一感染且有心代谢风险者中,MRI-PDFF诊断的脂肪变患病率达64%。
  • 脂肪变患者中11.3%肝硬度≥9.6 kPa,提示晚期纤维化。
  • CAP以280 dB/m为最佳界值诊断中重度脂肪变,曲线下面积0.86。

核心结论

  • 在有NAFLD风险的HIV单一感染大型队列中,约三分之二存在脂肪变,约10%有晚期纤维化,CAP对此人群脂肪变筛查准确。

研究设计与样本

  • 欧洲多中心前瞻性研究,纳入HIV单一感染、非过量饮酒且有代谢综合征和/或持续肝酶升高和/或临床脂肪营养不良的患者。
  • 2014年3月至2015年11月入组442例,最终分析402例;男性85%,中位年龄55岁(IQR 50-61岁),BMI 27.0 kg/m²(IQR 23.6-28.7 kg/m²),代谢综合征67%,CD4计数630/mm³(IQR 510-832/mm³)。
  • 所有参与者接受MRI-PDFF、Fibroscan/CAP及细胞因子和基因分析。

主要发现

  • 402例中257例(64%)有NAFLD(MRI-PDFF≥5%)。
  • 脂肪变患者中11.3%肝硬度≥9.6 kPa,提示晚期纤维化。
  • 多因素分析识别7个脂肪变相关因素:高CD4计数(OR 4.04;95%CI 1.92-8.51)、高瘦素水平(OR 2.12;95%CI 1.14-3.93)、非CC PNPLA3 rs738409基因多态性(OR 1.92;95%CI 1.11-3.33)、低HDL(OR 1.83;95%CI 1.03-3.27)、高甘油三酯(OR 1.48;95%CI 1.18-1.84)、ALT升高(OR 1.23;95%CI 1.16-1.31)、高铁蛋白血症(OR 1.05;95%CI 1.03-1.07)。
  • 晚期纤维化相关因素:高BMI(OR 1.23;95%CI 1.07-1.42;P=.005)和AST升高(OR 1.03;95%CI 1.01-1.05;P=.001)。
  • 以MRI-PDFF为参考,CAP最佳界值280 dB/m诊断中重度脂肪变的曲线下面积为0.86(95%CI 0.82-0.90)。

关键数值与推荐

  • NAFLD定义为MRI-PDFF≥5%。
  • 晚期纤维化提示指标为肝硬度≥9.6 kPa。
  • CAP诊断中重度脂肪变的最佳界值为280 dB/m,曲线下面积0.86(95%CI 0.82-0.90)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is a growing concern in the aging population with human immunodeficiency virus (HIV). Screening for NAFLD is recommended in patients with metabolic risk factors or unexplained transaminitis. This study aimed to prospectively assess the prevalence and associated factors of liver steatosis and advanced fibrosis (AF) in HIV-monoinfected patients at risk of NAFLD. METHODS: We conducted a multicenter study in HIV-monoinfected patients, nonexcessive drinkers with metabolic syndrome, and/or persistently elevated liver enzymes, and/or clinical lipodystrophy. All participants had magnetic resonance imaging proton density fat fraction (MRI-PDFF), Fibroscan/controlled attenuation parameter (CAP), and cytokine and genetic analysis. RESULTS: From March 2014 to November 2015, we enrolled 442 participants and analyzed 402: male (85%); median age, 55 years (interquartile range [IQR], 50-61 years); body mass index, 27.0 kg/m2 (IQR, 23.6-28.7 kg/m2); metabolic syndrome (67%); and CD4 cell count, 630/mm3 (IQR, 510-832/mm3). Overall 257 of 402 (64%) had NAFLD (MRI-PDFF ≥5%). Among them, 11.3% had a liver stiffness ≥9.6 kPa, suggestive of AF. Multivariable analysis identified 7 factors of steatosis: high CD4-cell count (odds ratio [OR], 4.04; 95% confidence interval [CI], 1.92-8.51), high leptin level (OR, 2.12; 95% CI, 1.14-3.93), non-CC PNPLA3s738409 genetic polymorphism (OR, 1.92; 95% CI, 1.11-3.33), low high-density lipoprotein (OR, 1.83; 95% CI, 1.03-3.27), high triglycerides (OR, 1.48; 95% CI, 1.18-1.84), elevated alanine transaminase (OR, 1.23; 95% CI, 1.16-1.31), and hyper ferritinemia (OR, 1.05; 95% CI, 1.03-1.07). Two factors were associated with AF: high body mass index (OR, 1.23 ; 95% CI, 1.07-1.42 ; P = .005, and elevated aspartate aminotransferase (OR, 1.03; 95% CI, 1.01-1.05; P = .001). Using MRI-PDFF as a reference, CAP (best cutoff, 280 dB/m) had good accuracy (area under the receiver operating characteristic curve = 0.86; 95% CI, 0.82-0.90) for the diagnosis of moderate to severe steatosis. CONCLUSIONS: In a large cohort of HIV-moninfected patients at risk of NAFLD, steatosis is present in two-thirds of cases, and around 10% have AF. The CAP technique is accurate for screening steatosis in this population.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lemoine M, Assoumou L, Girard PM, et al. Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study. Clin Gastroenterol Hepatol. 2022. PMID: 35436624. doi:10.1016/j.cgh.2022.03.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。